INDP vs. VINC, NERV, NRSN, VBIV, AYTU, TLPH, ORGS, TRAW, VAXX, and APM
Should you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Vincerx Pharma (VINC), Minerva Neurosciences (NERV), NeuroSense Therapeutics (NRSN), VBI Vaccines (VBIV), Aytu BioPharma (AYTU), Talphera (TLPH), Orgenesis (ORGS), Traws Pharma (TRAW), Vaxxinity (VAXX), and Aptorum Group (APM). These companies are all part of the "pharmaceutical preparations" industry.
Vincerx Pharma (NASDAQ:VINC) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, community ranking, media sentiment, dividends, profitability and analyst recommendations.
Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.
Vincerx Pharma received 10 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Indaptus Therapeutics an outperform vote while only 64.52% of users gave Vincerx Pharma an outperform vote.
In the previous week, Indaptus Therapeutics had 5 more articles in the media than Vincerx Pharma. MarketBeat recorded 6 mentions for Indaptus Therapeutics and 1 mentions for Vincerx Pharma. Indaptus Therapeutics' average media sentiment score of 1.89 beat Vincerx Pharma's score of 1.19 indicating that Vincerx Pharma is being referred to more favorably in the media.
44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 22.9% of Vincerx Pharma shares are owned by company insiders. Comparatively, 27.1% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Vincerx Pharma's return on equity of -108.14% beat Indaptus Therapeutics' return on equity.
Vincerx Pharma currently has a consensus price target of $5.00, suggesting a potential upside of 557.89%. Indaptus Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 466.04%. Given Indaptus Therapeutics' higher possible upside, equities analysts clearly believe Vincerx Pharma is more favorable than Indaptus Therapeutics.
Vincerx Pharma has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.
Summary
Indaptus Therapeutics beats Vincerx Pharma on 7 of the 13 factors compared between the two stocks.
Get Indaptus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indaptus Therapeutics Competitors List
Related Companies and Tools
